Similarly, CD4+ cell populations were found to be necessary for the complete efficacy of combined oncolytic herpes simplex virus (oHSV ΔG47-mIL12) and immune checkpoint inhibitor therapy in two distinct murine derived glioma models [22]. The gene discussed is CD4; the disease is central nervous system cancer.